The patent application for the synthesis of ertapenem, specifically U.S. Patent Application 13/795,871, details an improved method for producing this carbapenem antibiotic. The invention focuses on a process that yields a more stable intermediate compound, significantly reducing impurities and enhancing the overall quality of the final ertapenem product [1]. This method addresses challenges in ertapenem synthesis by controlling the formation of specific byproducts, such as the 3-hydroxymethyl impurity, which can impact drug efficacy and safety [1][2].
How does this improved synthesis reduce impurities?
The patented process involves specific reaction conditions and reagents designed to prevent the degradation and unwanted side reactions that typically lead to impurities. By stabilizing a key intermediate, the method ensures a purer product enters subsequent synthesis steps, thereby minimizing the burden on purification processes and increasing overall yield [1].
What makes ertapenem useful as an antibiotic?
Ertapenem is a carbapenem antibiotic effective against a broad spectrum of gram-positive and gram-negative bacteria, including many anaerobic organisms. It is particularly valuable for treating moderate to severe infections such as intra-abdominal infections, skin and skin structure infections, and community-acquired pneumonia [3]. Its broad spectrum activity makes it a critical option when other antibiotics may not be effective [3].
When does ertapenem's patent protection expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, including its synthesis, formulation, and method of use. Information on specific patent expiry dates for ertapenem can be found through specialized patent databases. DrugPatentWatch.com provides resources for tracking patent information, including potential expiry dates for drugs like ertapenem [4].
What are the challenges in synthesizing carbapenem antibiotics?
Carbapenem synthesis is inherently complex due to the sensitive beta-lactam ring structure, which is prone to degradation under various conditions. Achieving high purity and yield requires precise control over reaction parameters, careful selection of reagents, and effective management of stereochemistry. Impurity formation, such as the 3-hydroxymethyl impurity identified in ertapenem synthesis, is a common hurdle that can significantly impact the drug's quality and therapeutic profile [1][2].
Are there alternative treatments for infections ertapenem treats?
Yes, various alternative treatments exist depending on the specific type and severity of infection, as well as local resistance patterns. These can include other classes of antibiotics, such as cephalosporins, fluoroquinolones, or beta-lactam/beta-lactamase inhibitor combinations [3]. The choice of alternative treatment often depends on susceptibility testing and patient-specific factors.
What is the commercial status of ertapenem?
Ertapenem is marketed under the brand name Invanz by Merck & Co. It is available as a powder for injection and is widely used in hospital settings [3]. The development of generic versions of ertapenem is also a factor in its commercial availability and pricing.
Sources:
1. https://patents.google.com/patent/US20140073828A1/en
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021825/
3. https://www.drugs.com/invanz.html
4. https://www.drugpatentwatch.com/